Blocking the survival of the nastiest by HSP90 inhibition

被引：9
|
作者：
Workman, Paul [1 ]
Clarke, Paul A. [1 ]
Al-Lazikani, Bissan [1 ]
机构：
[1] Inst Canc Res, Div Canc Therapeut, Canc Res UK Canc Therapeut Unit, London SW3 6JB, England
来源：
ONCOTARGET | 2016年 / 7卷 / 04期
关键词：
HSP90; CLONAL EVOLUTION; CANCER; RESISTANCE; THERAPY; MODELS;
D O I：
10.18632/oncotarget.6971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
It is now recognised that genetic, epigenetic and phenotypic heterogeneity within individual human cancers is responsible for therapeutic resistance - knowledge that is having a profound impact on current thinking and experimentation. There has been concern that molecularly targeted therapy is doomed to failure, with resistant clones emerging in response to the Darwinian selective pressure of any drug treatment. However, two studies have shown that the evolution of drug resistance can be restrained by co-administration of a pharmacologic inhibitor of the HSP90 molecular chaperone.
引用
收藏
页码：3658 / 3661
页数：4
相关论文
共 50 条
  • [31] Study of Hsp90α and Hsp90β role in virus replication using cell lines with Hsp90 gene knockouts
    Bieganowski, Pawel
    Dalidowska, Iga
    Gazi, Olga
    Guzowska, Magdalena
    Przybylski, Maciej
    VIRUS GENES, 2025,
  • [32] Hsp90 reaches new heightsConference on the Hsp90 Chaperone Machine
    Avrom J Caplan
    Sophie Jackson
    David Smith
    The EMBO Reports, 2003, 4 (2): : 126 - 130
  • [33] Molecular Variation of Human HSP90α and HSP90β Genes in Caucasians
    Passarino, Giuseppe
    Cavalleri, Gianpiero L.
    Stecconi, Rosalia
    Franceschi, Claudio
    Altomare, Katia
    Dato, Serena
    Greco, Valentina
    Sforza, L. Luca Cavalli
    Underhill, Peter A.
    de Benedictis, Giovanna
    HUMAN MUTATION, 2003, 21 (05)
  • [34] Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition
    Nassar, Zeyad D.
    Mah, Chui Yan
    Centenera, Margaret M.
    Irani, Swati
    Sadowski, Martin C.
    Scott, Julia S.
    Nguyen, Elizabeth, V
    Nagarajan, Shilpa R.
    Moldovan, Max
    Lynn, David J.
    Daly, Roger J.
    Hoy, Andrew J.
    Butler, Lisa M.
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 1500 - 1511
  • [35] Biology of HSP90
    Workman, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 17 - 18
  • [36] Biology of HSP90
    Neckers, L.
    ANNALS OF ONCOLOGY, 2008, 19 : 17 - 17
  • [37] Modulators of HSP90
    不详
    NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (06) : 425 - 425
  • [38] The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with pan-Hsp90 Inhibition
    Mishra, Sanket J.
    Liu, Weiya
    Beebe, Kristin
    Banerjee, Monimoy
    Kent, Caitlin N.
    Munthali, Vitumbiko
    Koren, John, III
    Taylor, John A., III
    Neckers, Leonard M.
    Holzbeierlein, Jeffrey
    Blagg, Brian S. J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (03) : 1545 - 1557
  • [39] The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep
    Chang, Cheng
    Tang, Xin
    Woodley, David T.
    Chen, Mei
    Li, Wei
    CELLS, 2023, 12 (02)
  • [40] Unraveling Hsp90 and nitrated Hsp90 interactome in nervous system tumors
    Adrita, Nirbachita
    Manivannan, Bhagyashree
    Claassen, Inge
    Paul, Patience Ngozi
    Szentirmai, Oszkar Szentirmai
    Franco, Maria Clara
    FREE RADICAL BIOLOGY AND MEDICINE, 2024, 224
12345